Stool Transplants to Treat Refractory Clostridium Difficile Colitis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02127398 |
Recruitment Status :
Recruiting
First Posted : April 30, 2014
Last Update Posted : July 2, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Clostridium Difficile Colitis | Biological: fecal microbiota | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 10 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Fecal Microbiota Transplantation in Refractory Clostridium Difficile Colitis |
Study Start Date : | April 2016 |
Estimated Primary Completion Date : | May 2022 |
Estimated Study Completion Date : | May 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: fecal microbiota transplantation
fecal microbiota transplantation
|
Biological: fecal microbiota
fecal microbiota in capsule form |
- Recurrent colitis due to Clostridium difficile [ Time Frame: six months ]Patients will be followed 1, 7, 28, and 180 days after the treatment and success will be defined as resolution of C. difficile infection without recurrence within a six-month time period. Patients will be assessed by interview and physical exam. Any patients with suspected persisting/recurring C. difficile colitis will undergo further evaluation with a repeat stool C. difficile toxin assay.
- Tolerability of oral fecal microbiota transplantation [ Time Frame: six months ]We will monitor for side effects during the administration of the fecal microbiota capsules by close observation within the clinic for one hour. All subjects will return 24 hours after administration for repeat examination and for repeat assessment of tolerability using a questionnaire. Symptoms that will be specifically monitored include the patient's subjective measure of nausea, vomiting, abdominal cramping/pain, belching, diarrhea, constipation, and changes in the quantity or quality of stool.
- Safety of oral fecal microbiota transplantation [ Time Frame: six months ]The main safety concern is for the transmission of infection from the donor to the recipient. At each follow-up visit (1, 7, 28, and 180 days after treatment) subjects will be assessed for any signs or symptoms of infection by history and physical exam. Some of the specific infections that will be considered will be infectious colitis, infection due to Helicobacter pylori, viral hepatitis, and HIV infection. Patients with signs or symptoms of a suspected infection will undergo appropriate workup with blood and/or stool studies.
- rate of repeat therapy for C. difficile colitis within 6 months of fecal microbiota transplantation. [ Time Frame: six months ]All subjects will return for evaluation with a comprehensive history and physical exam 180 days after fecal microbiota transplantation, and patients will be asked if they have required any form of therapy for C. difficile colitis in the interim.
- Rate of hospitalization [ Time Frame: six months ]
- Mortality [ Time Frame: six months ]Number of people who die
- Rate of adverse events [ Time Frame: six months ]number of serious AE's occurring within 6 months of transplant

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Study entry is open to adults (>18 years old) who have had three of more episodes of Clostridium difficile colitis within the previous 12 months.
Exclusion Criteria:
- Absolute neutrophil count < 500 cells/mm3
- Active infection at other sites (excluding Clostridium difficile) requiring ongoing antibacterial therapy (antiviral or antifungal therapy is acceptable)
- Current or planned cytotoxic chemotherapy within 14 days of the potential fecal transplantation date
- Life expectancy <180 days
- Diagnosis of inflammatory bowel disease (e.g. Crohn's or ulcerative colitis)
- Inability to swallow capsules
- Indwelling nasogastric, orogastric, gastrostomy, or jejunostomy tube
- History of partial or total gastrectomy
- Short gut syndrome requiring total parenteral nutrition
- Pregnancy
- Documented intestinal parasite infection without documentation of appropriate treatment

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02127398
Contact: Gary M Cox, MD | 919-668-3271 | gary.cox@duke.edu |
United States, North Carolina | |
Duke University Medical Center | Recruiting |
Durham, North Carolina, United States, 27710 | |
Contact: Gary M Cox, MD 919-668-3271 gary.cox@duke.edu | |
Principal Investigator: Gary M Cox, MD |
Principal Investigator: | Gary M Cox, MD | Duke University |
Responsible Party: | Duke University |
ClinicalTrials.gov Identifier: | NCT02127398 History of Changes |
Other Study ID Numbers: |
Pro00053348 |
First Posted: | April 30, 2014 Key Record Dates |
Last Update Posted: | July 2, 2019 |
Last Verified: | July 2019 |
C. difficile colitis fecal microbiota transplantation |
Clostridium Infections Enterocolitis, Pseudomembranous Colitis Gastroenteritis Gastrointestinal Diseases Digestive System Diseases |
Colonic Diseases Intestinal Diseases Gram-Positive Bacterial Infections Bacterial Infections Enterocolitis |